LIFEVANTAGE CORP Other than Temporary Impairment Losses, Investments
LIFEVANTAGE CORP (LFVN) reported Other than Temporary Impairment Losses, Investments of $0 for the 12-month period ending 2023-06-30, per its 10-K filed 2023-08-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfInvestments · last filed 2023-08-28
- LIFEVANTAGE CORP other than temporary impairment losses, investments for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- LIFEVANTAGE CORP other than temporary impairment losses, investments for fiscal 2022 was $2.21M.
- LIFEVANTAGE CORP other than temporary impairment losses, investments for fiscal 2021 was $0.00.
- LIFEVANTAGE CORP other than temporary impairment losses, investments for fiscal 2020 was $0.00.
| Period end | Other than Temporary Impairment Losses, Investments 12 month |
|---|---|
| 2023-06-30 | $0.00 10-K · filed 2023-08-28 |
| 2022-06-30 | $2.21M 10-K · filed 2023-08-28 |
| 2021-06-30 | $0.00 10-K · filed 2022-08-23 |
| 2020-06-30 | $0.00 10-K · filed 2022-08-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |